Alcon to Launch Clareon IOL at ESCRS Meeting

October 6, 2017: By Joan McKenna

alcon-large-3x2Alcon will introduce its new Clareon intraocular lens (IOL) at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, set for Oct. 7-11 in Lisbon, Portugal.

The company describes the Clareon as having the most advanced optic IOL material available. The lens is offered in an automated, disposable, preloaded delivery system.

Alcon, the Texas-based eye care division of Novartis, says it will provide an extensive scientific and educational program at the meeting, with 18 accepted abstracts and more than 10 satellite events.

“We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space,” said Mike Ball, chief executive officer of Alcon. “This is a great year for Alcon as we celebrate many important milestones.”

Among those is the 100 millionth implantation of Alcon’s flagship AcrySof lens, Ball said.

Presentations also will include new efficacy and safety data for Alcon’s CyPass Micro-Stent in patients with glaucoma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022